Heart failure & cardiomyopathies
SGLT2 Inhibitor Therapy for Transthyretin Amyloid Cardiomyopathy: Early Tolerance and Clinical Response to Dapagliflozin
Authors' conclusion
In tafamidis-treated ATTR-CM patients, initiation of dapagliflozin was well tolerated.
Study context
- Population
- Patients with stable, tafamidis-treated transthyretin amyloid cardiomyopathy (ATTR-CM)SGLT2i initiated in 34
- Participants
- 17 vs 40
- Exposure
- Dapagliflozin vs no SGLT2 inhibitor in tafamidis-treated ATTR-CM
- Dapagliflozinn = 17
- Controln = 40reference
- Outcome
- Tolerability, clinical outcomes and changes in NT-proBNP and glomerular filtration rate (GFR)
- Follow-up
- 3 months
Main finding
As reported in the abstract
Change in NT-proBNP
| Group | Value | Numerical decrease | P |
|---|---|---|---|
| Dapagliflozin | −190 (IQR −1,028–71) pg/mL | 13/17 (76.5%) | P = 0.557 |
| Control | −115 (IQR −357–105) pg/mL | 27/40 (67.5%) | P = 0.551 |
Value
Dapagliflozin−190 (IQR −1,028–71) pg/mL
Control−115 (IQR −357–105) pg/mL
Numerical decrease
Dapagliflozin13/17 (76.5%)
Control27/40 (67.5%)
P
DapagliflozinP = 0.557
ControlP = 0.551
Observational data: associations, not effects.
Safety
- Adverse events — Dapagliflozin
- 0 events
Original publication
SGLT2 Inhibitor Therapy for Transthyretin Amyloid Cardiomyopathy: Early Tolerance and Clinical Response to Dapagliflozin. ESC Heart Fail. Published 19 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →